Make it or break it?I've been puzzled by the X publications recently, why bother about South Korea when efforts should be directed to North America for the planned launch?
Also, still no word about the launch partner.
My interpretation is that they try to attract contracts in order to limit the need of launch partner capital and that's a good strategy. It will also take some time until they will get a decent sales cash flow so any contract is welcome.
As long I'm invested I believe in a success, think it's still reachable even though the window probably close in 2025. If successful, I think this company could be THE turn-around of the year.
Before some of the idiots on this board made biorun to leave he shared with me that Abbvie probably would launch their product in Jan 2025. I thought it should be one year earlier but found myself corrected. Let's see if the same applies to him or if we will enjoy a pleasent surprise.